ChemoCentryx: Phase II Trial In Diabetic Nephropathy With CCX140 Meets Endpoint

(RTTNews) - ChemoCentryx Inc. (CCXI) announced positive top-line 52-week data from its Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2. The trial met its primary endpoint.

The company reported that the Phase II trial demonstrated that treatment with 5 mg of CCX140 given orally once daily added to a standard of care regimen (SOC) of angiotensin converting enzyme inhibitor or angiotensin receptor II blocker treatment resulted in a statistically significant reduction in urinary albumin creatinine ratio, beyond that achieved with SOC alone. The maximum treatment effect (24 percent reduction) was reached at 12 weeks, and sustained reduction in albuminuria induced by CCX140 relative to SOC alone was observed over the full year.

"These positive data suggest that treatment with CCX140 may result in clinically meaningful improvements in kidney function when added to standard of care in patients with chronic kidney disease. Given the positive improvements in albuminuria and eGFR observed in this clinical trial, we believe we have an effective dose of CCX140 to take forward into a Phase III clinical trial in diabetic nephropathy, and that we are well positioned to advance partnering discussions as well as an end of Phase II meeting with the FDA," said Thomas Schall, President and CEO, ChemoCentryx.

The company said CCX140 appeared to be well tolerated with a low overall dropout rate over the 52-week treatment period (10 percent). No safety issues were observed that would prevent further clinical development of CCX140 in diabetic nephropathy.